Clinical trial
A Phase II/III Study to Evaluate the Efficacy and Safety of SYS6010 in Combination With SG001 With or Without 5-FU/Capecitabine in Subjects With First-Line Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
NCT07251062 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II/III Study to Evaluate the Efficacy and Safety of SYS6010 in Combination With SG001 With or Without 5-FU/Capecitabine in Subjects With First-Line Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- December 30, 2025
- Completion date
- December 30, 2030
- Enrollment
- 737 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.